Preface

Frontiers in Clinical Drug Research - Anti-Cancer Agents presents recent developments in various therapeutic approaches against different types of cancer. The book is a valuable resource for pharmaceutical scientists, postgraduate students, and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research.

The five chapters in this volume are written by eminent authorities in the field. Chapter 1 deals with the role of the PI3K/AKT/mTOR pathway in the survival of malignant cells as a potential target to combat relapse in AML patients. It also covers therapeutic agents involving a new class of inhibitors for plausible approaches to treat patients with relapsed or refractory AML diseases. Chapter 2 discusses the role of some natural products as potential novel anti-tumor agents treat CRPC patients. Chapter 3 presents an overview of key proteins and their coordinating and/or cooperating partner proteins in protein pathways which can be useful to design innovative chemotherapeutics. Chapter 4 deals with the effectiveness of Hepatic Arterial Infusion Chemotherapy (HAIC) for advanced hepatocellular carcinoma. Chapter 5 summarizes the current strategies and discusses lead molecules which have found their way to preclinical and clinical studies for targeting cancer stem cells.


I hope that the readers will find these reviews valuable and thought-provoking so that they may trigger further research in the quest for new and novel therapies against cancers.

I am grateful for the timely efforts made by the editorial personnel, especially Mr. Mahmood Alam (Director Publications) and Mrs. Salma Sarfaraz (Senior Manager Publications) at Bentham Science Publishers.